rence of angiographic restenosis after coronary balloon angioplasty. The mechanism by which restenosis occurs after coronary artery intervention may differ between conventional balloon angioplasty and intracoronary stent implantation. 12 In-stent restenosis results predominantly from neointimal hyperplasia consisting of smooth muscle cell migration and extracellular matrix formation, 6 not from late recoil. The present study was designed to evaluate the relationship between the effect of quinapril, a tissue-specific ACE inhibitor with high affinity 13 and an insertion/deletion (I/D) polymorphism of the ACE gene on the prevention of restenosis after coronary stent implantation. 14 We present our data from quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) carried out in patients who underwent successful coronary stent implantation.
Methods

Study Population
The study population consisted of 100 consecutive patients who underwent successful implantation of a Palmaz-Schatz stent in Ogaki Municipal Hospital. The aim of the coronary stenting was an 'optimal' result after elective balloon angioplasty for an angiographically proven, functionally significant narrowing in major coronary arteries. All of the patients were prospectively asked to undergo a systematic 6-month angiographic follow-up. Patients were randomly assigned to the quinapril treatment group (10 mg or 20 mg of quinapril daily (average dose of 18 mg/day) from the day after stenting) or the control group Circ J 2002; 66: 311 -316 (Received August 24, 2001 ; revised manuscript received December 4, 2001 ; accepted December 26, 2001) Internal Medicine II, Nagoya University School of Medicine, Nagoya and *Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan Mailing address: Kenji Okumura, MD, Second Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: kenji@med.nagoya-u. ac.jp after stent implantation. No placebo tablets were administered in the control group. There was no protocol regarding calcium antagonists, nitrates or -blockers. The aims of the study were explained to each patient and informed consent was obtained. The trial was carried out according to the Declaration of Helsinki.
Angioplasty and Stenting Procedures
Treatment with 200 mg ticlopidine and 81 mg aspirin was administered daily before the procedure and continued until the time of follow-up. Balloon dilatation was performed according to the conventional technique. A PalmazSchatz stent with delivery sheath developed at nominal pressures was used; each stent was then expanded with a noncompliant balloon of the same diameter as the reference vessel segment, with inflation in the range of 14-16 atm for 30-60 s.
Angiographic Assessment and QCA
A coronary arteriogram was obtained before balloon angioplasty, after stent replacement, and at follow-up after the administration of 0.2 mg intracoronary nitroglycerin. QCA was performed independently by 2 core angiographic laboratories blinded to the treatment assignment. Reference lumen diameter and minimal lumen diameter were determined by a computer-assisted, edge-detection algorithm using an offline system (QCA-CMS System, MEDIS Inc). Follow-up angiography was performed in the same projections as those used in the baseline study. Using the outer diameter of the contrast-filled catheter as the calibration, the minimal lumen diameter in diastole from the 'worst' view was recorded. The reference was averaged from 10-mmlong angiographically normal segments proximal and distal to the lesion; when a normal proximal segment could not be identified (eg, ostial lesion location), only a distal segment was analyzed. The percent diameter stenosis was calculated from the minimal lumen diameter and the reference. To define restenosis, we used a categorical approach with the criterion of ≥50% diameter narrowing within the stent and in the segment, including the stent plus its edges (within 5 mm) at follow-up.
IVUS Measurements
The IVUS system (Cardiovascular Imaging Systems, Inc, Boston, MA, USA) incorporated a 30-MHz beveled transducer mounted on the end of a flexible shaft that rotates at 1,800 rpm within a 3.2F imaging sheath (Ultra Cross TM 3.2; Boston Scientific SCIMED, Natick, MA, USA). All studies were recorded during transducer pullback on a high resolution super-VHS tape for off-line analysis at a pullback speed of 0.5 mm/s. The cross-sectional area of intimal hyperplasia present within the stent was calculated as the stent cross-sectional area minus the lumen cross-sectional area. The reference lumen cross-sectional areas were the lumen areas at the most visually normal anatomic cross sections within 10 mm proximal and distal to the stent but before any major side branches. When a stent was ostial in location, only the distal reference lumen was measured.
DNA Analysis for the Detection of ACE Genotype
ACE polymorphism was obtained in 92 of the 99 patients analyzed in our initial study. 14 In that study there were 46 subjects in the control and quinapril groups each. The quinapril and control groups were then divided into 2 subgroups: patients with the D allele (DD and ID genotype) and patients without (II genotype). Samples of venous blood for DNA analysis were collected after follow-up coronary angiography. Leukocytes were isolated from blood samples containing ethylene diamine tetraacetic acid (EDTA) disodium using Ficoll-Hypaque solution (Pharmacia, Uppsala, Sweden). 15 DNA was extracted from the lymphocytes with the use of a QIAamp Blood Kit (QIAGEN Inc, Chatsworth, CA, USA). The I/D polymorphism of the ACE gene was determined in the presence of 5% dimethysulfoxide to enhance amplification of the ACE I allele according to a method previously described. 14 Reaction products were loaded onto a 2.0% agarose gel and electrophoresed, then the gel was treated with ethidium bromide. DNA fragments were confirmed by comparison with known size markers.
Baseline Data Collection
A history of smoking was obtained during subject interviews. The subjects with a history of taking medication for hypertension or those whose average blood pressure was ≥90 mmHg in diastole and/or ≥140 mmHg in systole by 2 or more measurements were labeled as hypertensive. Diabetes mellitus was diagnosed by the 1997 criteria of the American Diabetes Association. The body mass index (BMI) was calculated as weight divided by height squared (kg/m 2 ). Fasting blood samples were collected for plasma lipid concentrations. Plasma levels of total cholesterol and those of triglycerides were measured by enzymatic methods. The plasma level of high-density lipoprotein (HDL) cholesterol was determined with enzymatic reagents after precipitating the apolipoprotein B-containing lipoproteins with heparin, Ca 2+ , and Ni 2+ . The concentration of low-density lipoprotein (LDL) cholesterol was calculated with the formula described by Friedewald et al. 17 
Statistical Analysis
The results are shown as mean ± SD. Data were collected and stored in an Apple computer (Apple Japan Inc, Tokyo, Japan) using Statview 5.0 software (SAS Institute Inc, Cary, NC, USA). One-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls multiple-range test as a post hoc test, or by the chi-square test, as appropriate, was used to compare the differences between 2 groups. A level of p<0.05 was considered significant.
Results
Follow-up angiography and ACE polymorphism analysis were obtained from 92 patients: 46 in the control group and 46 in the quinapril treatment group. There were no significant differences between the control and quinapril treatment groups with regard to lesion characteristics such as location or lesion type ( Table 1) .
Results of the ACE I/D polymorphism revealed that there were 23 subjects with genotype II, 8 with ID, and 15 with DD in the control group, and 26 with II, 14 with ID, and 6 with DD in the quinapril treatment group, indicating that there was no significant difference in the distribution of ACE genotype between the 2 groups. Given that the number of subjects enrolled in the present study was small, and that the D allele dominant effect was more prominent than its recessive effect in the results, the subjects were divided into 2 subgroups, those with the D allele (ID+DD group) and those without (II group).
The 4 groups divided according to treatment and genotype were well matched for age and sex. The prevalence of risk factors such as BMI, smoking habit, hypertension, and diabetes did not differ statistically among the groups (Table 2) . Likewise, there were no significant differences in plasma lipid concentrations among the groups, although total cholesterol and LDL cholesterol concentrations showed a tendency toward lower levels in the ID+DD subgroup of both the control and quinapril treatment groups.
Follow-up coronary angiography was performed at 6 months after stent implantation and the angiographic characteristics by QCA analysis are shown in Table 3 . Restenosis in the ID+DD group of the quinapril treatment group was observed in only 1 patient, though there was no statistically significant difference in the occurrence of restenosis among the groups (p=0.29). QCA analysis showed no differences in the reference diameter among the groups before intervention, after intervention, or at follow-up angiography. With regard to minimal lumen diameter of stents at followup angiography, a significantly higher dimension was obtained in the ID+DD group of the quinapril treatment group as compared with that in the ID+DD group of the control or the II group of the quinapril treatment group (2.33±0.86 mm vs 1.95±0.58 mm or 1.91±0.75 mm, respec- tively; p<0.05), despite a lack of difference in minimal lumen diameter before and after intervention. On the other hand, the percent diameter stenosis at angiographic followup was significantly lower in the ID+DD group of the quinapril treatment group than that in the ID+DD group in the control or in the II group of the quinapril treatment group (22.9±22.6 vs 37.1±19.7 or 36.4±22.6%, respectively; p<0.05). When the subjects were not divided according to the genotype, the preventive effect of quinapril treatment was not observed. In a small number of patients, we assessed in-stent restenosis using IVUS (Table 4) . IVUS analysis also revealed that quinapril treatment of patients with the D allele prevented the loss of minimal lumen cross-sectional area (5.2±1.1 vs 3.3±1.1 mm 2 in the control patients with the D allele, p<0.01) and attenuated the increase in percent area stenosis calculated from the stent cross-sectional areas (34.5±14.0 vs 53.3±16.4% in the control patients with the D allele, p<0.05).
Discussion
We recently reported on the effect of quinapril on in-stent restenosis in 99 patients who underwent successful coronary angioplasty and stent implantation. 14 In our study, based on IVUS analysis, quinapril treatment attenuated the decrease in minimal luminal area and lumen volume at 6 months in stented coronary artery segments. However, angiographic analysis failed to demonstrate a significant difference in minimal luminal diameter between the quinapril and control groups at 6 months. Quinapril has high tissue specificity for ACE, and the dissociation of the drug from the enzyme is markedly prolonged. 13 ACE inhibition with quinapril treatment can ameliorate endothelial dysfunction, which may be one of the first steps in the development of atherosclerosis, 18 in patients with coronary artery disease. 19 The present study shows that the ACE inhibitor, quinapril, has a potential protective effect on late luminal narrowing after successful coronary artery stent implantation, and that susceptibility to the favorable effect on diminishing loss of lumen diameter is associated with ACE I/D polymorphism. Our data indicate that administration of the ACE inhibitor may be effective only in patients with the D allele.
Our study had some limitations. It was not double blind and additionally, a placebo tablet was not given to the control group. Lastly, the total and LDL cholesterol levels were lower in the patients with the D allele compared with patients without the D allele.
The renin -angiotensin system has been implicated in the pathogenesis of neointimal hyperplasia. 20 The I/D polymorphism in the ACE gene is associated with marked differences in serum 21 and cellular ACE levels. 22 Namely, individuals with the ACE D allele show higher levels of blood and cellular ACE concentrations. Although a recent report showed a slight association between ACE I/D polymorphism and the level of blood pressure in Japanese subjects, 23 most previous studies have reported no association. 24 Regarding ischemic heart disease, an up to date large-scale study discussing the association between myocardial infarction and the D allele, concluded that a weak relationship exists between the two (risk ratio 1.10, 95% confidence interval 1.00-1.21). 25 In addition, no influence of ACE polymorphism on restenosis after coronary angioplasty 26 or stent implantation 27 were reported, which is consistent with our results in the control group.
Evidence that ACE inhibitors effectively limit restenosis has been reported in animal models, 20, 28, 29 but has proven ineffective for restenosis in humans after coronary balloon angioplasty in multicenter, double-blind, placebo-controlled trials. [9] [10] [11] On the basis of the findings from animal models, restenosis was initially considered to occur because of neointimal hyperplasia in response to endothelial injury. 20 In contrast, intracoronary ultrasound studies in humans suggest that chronic remodeling rather than neointimal hyperplasia is the major mechanism of restenosis after conventional coronary balloon angioplasty. 30 On the other hand, the stent prevents the remodeling process as well as the elastic vessel recoil and plaque persistence; therefore, restenosis after coronary stenting is chiefly a consequence of neointimal hyperplasia in conjunction with the stent. 12 Thus, ACE inhibitors, which have been experimentally proven to have protective effects against neointimal hyperplasia, are more likely to prevent restenosis after stent implantation as compared with conventional balloon angioplasty. The results demonstrated here show that, on the basis of the findings shown in percent diameter stenosis by QCA analysis and percent area stenosis by IVUS analysis, quinapril treatment had no effect on the prevention of restenosis in the patients with the II genotype.
The result that only subjects with the D allele benefited from the preventive effect on restenosis by quinapril treatment could be attributed to higher levels of ACE activity in these subjects than in those with the II genotype. The subjects with the higher levels of ACE activity are considered to respond to ACE inhibitor treatment with a greater decrease in ACE activity. Amant et al have reported that
Control group
Quinapril group the D allele of the ACE gene is associated with greater late luminal loss after intracoronary stent implantation, most likely by higher levels of plasma ACE. 31 Our results do not conflict with their expectations. In fact, studies in patients with nephropathy showed that the improvement of proteinuria was greater in subjects with the D allele than in those with the II genotype. 32, 33 Recently, Prasad et al have reported that ACE inhibitor treatment results in a greater improvement of endothelial dysfunction in subjects with the D allele. 34 We expect that the II genotype patients with coronary artery stenosis have more risk factors than those with the D allele because the former group suffer from coronary heart disease even in the absence of the D allele. It should be noted that the levels of total plasma and LDL cholesterol in the subjects with the II genotype were higher than those in subjects with the D allele. It has been claimed that the protective effect on restenosis in subjects with the D allele is from the lower levels of LDL cholesterol in the ID+DD. In light of our finding that patients with the II genotype did not have a beneficial effect of the quinapril treatment, this favorable effect on restenosis was achieved by inhibition of the renin-angiotensin system. Given that multiple factors are associated with the development of neointimal hyperplasia, 6 sufficient protection from restenosis could not be obtained by the administration of an ACE inhibitor only. To our knowledge, the PARIS Study by Meurice et al is the only other published study on the effect of quinapril on in-stent restenosis. 35 Even though they reported a prostenotic effect with quinapril compared with placebo in patients with the DD ACE genotype, their study is not similar to our study. Most importantly, the ethnic backgrounds of the patients are different. Because the sample sizes are small, the PARIS Study and ours are only pilot studies and further studies are required before a definitive conclusion can be made on the effect, if any, of quinapril on coronary artery in-stent restenosis.
Our results suggest that the administration of ACE inhibitors for the attenuation of the lumen loss after coronary stent implantation is more beneficial in subjects with the D allele of the ACE genotype. In other words, treatment with an ACE inhibitor is not expected to result in inhibition of neointimal hyperplasia in subjects with the II genotype. The determination of the ACE genotype in patients will enable selective treatment for patients after coronary artery intervention.
